Fate Therapeutics Inc - Asset Resilience Ratio
Fate Therapeutics Inc (FATE) has an Asset Resilience Ratio of 50.86% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Fate Therapeutics Inc current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2024)
This chart shows how Fate Therapeutics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see FATE asset base.
Liquid Assets Composition Over Time
This chart breaks down Fate Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore FATE long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $174.80 Million | 50.86% |
| Total Liquid Assets | $174.80 Million | 50.86% |
Asset Resilience Insights
- Very High Liquidity: Fate Therapeutics Inc maintains exceptional liquid asset reserves at 50.86% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Fate Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Fate Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 16.06% |
|
Genscript Biotech Corporation
F:G51 |
Biotechnology | 13.79% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
89bio Inc
NASDAQ:ETNB |
Biotechnology | 71.60% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 2.66% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
Annual Asset Resilience Ratio for Fate Therapeutics Inc (2013–2024)
The table below shows the annual Asset Resilience Ratio data for Fate Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 55.14% | $243.01 Million | $440.69 Million | +1.15pp |
| 2023-12-31 | 53.99% | $273.31 Million | $506.22 Million | +0.86pp |
| 2022-12-31 | 53.13% | $374.89 Million | $705.56 Million | +0.79pp |
| 2021-12-31 | 52.34% | $482.33 Million | $921.46 Million | +1.65pp |
| 2020-12-31 | 50.70% | $315.57 Million | $622.46 Million | +10.46pp |
| 2019-12-31 | 40.23% | $121.61 Million | $302.27 Million | +35.31pp |
| 2018-12-31 | 4.93% | $10.49 Million | $213.03 Million | -6.47pp |
| 2017-12-31 | 11.39% | $12.00 Million | $105.29 Million | +7.71pp |
| 2016-12-31 | 3.69% | $3.50 Million | $95.05 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $67.96 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $51.20 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $55.58 Million | -- |
About Fate Therapeutics Inc
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat… Read more